Abstract
Dietary niacin deficiency, and pharmacological excesses of nicotinic acid or nicotinamide, have dramatic effects on cellular NAD pools, ADP-ribose metabolism, tissue function and health. ADP-ribose metabolism is providing new targets for pharmacological intervention, and it is important to consider how the supply of vitamin B3 may directly influence ADP-ribosylation reactions, or create interactions with other drugs designed to influence these pathways. In addition to its redox roles, NAD+ is used as a substrate for mono-, poly- and cyclic ADP-ribose formation. During niacin deficiency, not all of these processes can be maintained, and dramatic changes in tissue function and clinical condition take place. Conversely, these reactions may be differentially enhanced by pharmacological intakes of vitamin B3, and potentially by changing expression of specific NAD generating enzymes. A wide range of metabolic changes can take place following pharmacological supplementation of nicotinic acid or nicotinamide. As niacin status decreases towards a deficient state, the function of other types of pharmaceutical agents may be modified, including those that target ADP-ribosylation reactions, apoptosis and inflammation. This article will explore what is known and yet to be learned about the response of tissues, cells and subcellular compartments to excessive and limiting supplies of niacin, and will discuss the etiology of the resulting pathologies.
Keywords: Niacin, ADP-Ribose, Metabolism, cellular NAD, nicotinic acid, vitamin B3, apoptosis, inflammation, etiology
Current Pharmaceutical Design
Title: Niacin Status, NAD Distribution and ADP-Ribose Metabolism
Volume: 15 Issue: 1
Author(s): James B. Kirkland
Affiliation:
Keywords: Niacin, ADP-Ribose, Metabolism, cellular NAD, nicotinic acid, vitamin B3, apoptosis, inflammation, etiology
Abstract: Dietary niacin deficiency, and pharmacological excesses of nicotinic acid or nicotinamide, have dramatic effects on cellular NAD pools, ADP-ribose metabolism, tissue function and health. ADP-ribose metabolism is providing new targets for pharmacological intervention, and it is important to consider how the supply of vitamin B3 may directly influence ADP-ribosylation reactions, or create interactions with other drugs designed to influence these pathways. In addition to its redox roles, NAD+ is used as a substrate for mono-, poly- and cyclic ADP-ribose formation. During niacin deficiency, not all of these processes can be maintained, and dramatic changes in tissue function and clinical condition take place. Conversely, these reactions may be differentially enhanced by pharmacological intakes of vitamin B3, and potentially by changing expression of specific NAD generating enzymes. A wide range of metabolic changes can take place following pharmacological supplementation of nicotinic acid or nicotinamide. As niacin status decreases towards a deficient state, the function of other types of pharmaceutical agents may be modified, including those that target ADP-ribosylation reactions, apoptosis and inflammation. This article will explore what is known and yet to be learned about the response of tissues, cells and subcellular compartments to excessive and limiting supplies of niacin, and will discuss the etiology of the resulting pathologies.
Export Options
About this article
Cite this article as:
Kirkland B. James, Niacin Status, NAD Distribution and ADP-Ribose Metabolism, Current Pharmaceutical Design 2009; 15 (1) . https://dx.doi.org/10.2174/138161209787185823
DOI https://dx.doi.org/10.2174/138161209787185823 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Matrix Metalloproteinases in Animal Models of Ischemic Stroke
Current Vascular Pharmacology Nitric Oxide Induced Damage and Preventive Effect of Curcumin and Quercetin on Buffalo Brain Cystatin
Current Proteomics Targeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Current Pharmaceutical Design Viral Inhibition of Tumour Necrosis Factor-α (TNFα) and TNF-Receptor Induced Apoptosis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
Current Pharmaceutical Design Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Novel Circular, Cyclic and Acyclic ψ(CH2O) Containing Peptide Inhibitors of SKI- 1/S1P: Synthesis, Kinetic and Biochemical Evaluations
Current Medicinal Chemistry Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Neuroinflammation, Microglia and Mast Cells in the Pathophysiology of Neurocognitive Disorders: A Review
CNS & Neurological Disorders - Drug Targets Insights into Immunophilin Structure and Function
Current Medicinal Chemistry Association of SORL1 Alleles with Late-Onset Alzheimer's Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis
Current Alzheimer Research Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways
Current Genomics Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design Anderson-Fabry Disease in Children
Current Pharmaceutical Design 5-HT1 Receptors
Current Drug Targets - CNS & Neurological Disorders Decreased Regenerative Capacity of Oligodendrocyte Progenitor Cells (NG2-Glia) in the Ageing Brain: A Vicious Cycle of Synaptic Dysfunction, Myelin Loss and Neuronal Disruption?
Current Alzheimer Research Meet Our Editorial Board Member
Current Alzheimer Research Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
CNS & Neurological Disorders - Drug Targets Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Current Alzheimer Research